XML 19 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (22,443,000) $ (13,214,000)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 953,000 1,260,000
Amortization of intangible assets 15,000 15,000
Amortization of finance lease right-of-use assets 68,000 203,000
Amortization of operating lease right-of-use assets 286,000 260,000
Depreciation of fixed assets 411,000 363,000
Accrued interest receivable on promissory note receivable (59,000) (47,000)
Amortization of premiums/(accretion of discounts) on debt securities (159,000) 0
Provision for credit losses 65,000 0
Impairment of intangible assets 5,003,000 0
Changes in operating assets and liabilities:    
Accounts receivable - trade (65,000) 0
Prepaid expenses and other current assets (1,529,000) (21,000)
Prepaid expenses - noncurrent (281,000) 0
Security deposit 16,000 0
Accounts payable 846,000 1,119,000
Accrued expenses 296,000 (704,000)
Operating lease obligations (363,000) (323,000)
Contract liabilities (50,000) 400,000
Net cash used in operating activities (16,990,000) (10,689,000)
Cash flows from investing activities:    
Purchases of debt securities (32,428,000) 0
Redemption of debt securities 5,400,000 0
Payment received for interest and principal on promissory note receivable   712,000
Purchases of fixed assets (559,000) (15,000)
Net cash (used in) provided by investing activities (27,587,000) 697,000
Cash flows from financing activities:    
Proceeds from sales of common stock 3,529,000 1,131,000
Proceeds from sales of pre-funded warrants 78,624,000 0
Proceeds from the exercise of warrants for common stock 7,870,000 0
Payments made for costs to acquire capital (5,710,000) 0
Proceeds from the exercise of stock options   130,000
Subscription receivable 105,000 0
Payment of equipment financing loan (64,000) (131,000)
Payment of term promissory note (657,000) (160,000)
Payment of finance lease obligation (53,000) (221,000)
Net cash provided by financing activities 83,644,000 749,000
Net increase (decrease) in cash, cash equivalents and restricted cash 39,067,000 (9,243,000)
Cash, cash equivalents and restricted cash - beginning 8,792,000 14,425,000
Cash, cash equivalents and restricted cash - end 47,859,000 5,182,000
Schedule of non-cash activities:    
Costs to raise capital included in accrued expenses 150,000 0
Reserves related to term promissory note included in prepaid expenses (109,000) 0
Unrealized loss on available-for-sale debt securities 21,000 0
Indefinite-lived intangible asset addition   750,000
Shares issued to AstralBio for license fee   (750,000)
Insurance premium financing   697,000
Supplemental cash flow information:    
Cash paid during the year for interest $ 72,000 $ 168,000